Merck & Co., Inc. (NYSE:MRK) Position Trimmed by Legacy Private Trust Co. Posted by Stephan Jacobs | Mar 16th, 2018 
Legacy Private Trust Co. lowered its position in shares of Merck & Co., Inc. (NYSE:MRK) by 37.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,228 shares of the company's stock after selling 3,740 shares during the period. Legacy Private Trust Co.'s holdings in Merck & Co., Inc. were worth $350,000 at the end of the most recent quarter. 
Several other hedge funds have also recently modified their holdings of MRK. Honeywell International Inc. raised its holdings in shares of Merck & Co., Inc. by 18.8% in the third quarter. Honeywell International Inc. now owns 633,700 shares of the company's stock valued at $40,576,000 after buying an additional 100,500 shares during the last quarter. Hanson McClain Inc. raised its holdings in shares of Merck & Co., Inc. by 65.0% in the second quarter. Hanson McClain Inc. now owns 7,662 shares of the company's stock valued at $491,000 after buying an additional 3,019 shares during the last quarter. D.A. Davidson & CO. raised its holdings in shares of Merck & Co., Inc. by 18.3% in the third quarter. D.A. Davidson & CO. now owns 524,481 shares of the company's stock valued at $33,582,000 after buying an additional 81,290 shares during the last quarter. Train Babcock Advisors LLC raised its holdings in shares of Merck & Co., Inc. by 19.8% in the fourth quarter. Train Babcock Advisors LLC now owns 10,810 shares of the company's stock valued at $609,000 after buying an additional 1,785 shares during the last quarter. Finally, Hartland & Co. LLC raised its holdings in shares of Merck & Co., Inc. by 9.5% in the second quarter. Hartland & Co. LLC now owns 44,558 shares of the company's stock valued at $2,856,000 after buying an additional 3,861 shares during the last quarter. Hedge funds and other institutional investors own 74.79% of the company's stock. Get Merck & Co. Inc. alerts: 
Merck & Co., Inc. ( NYSE:MRK ) traded up $0.45 during mid-day trading on Thursday, hitting $55.25. 10,080,000 shares of the stock traded hands, compared to its average volume of 13,010,000. Merck & Co., Inc. has a twelve month low of $53.12 and a twelve month high of $66.41. The firm has a market capitalization of $148,960.00, a price-to-earnings ratio of 30.36, a PEG ratio of 2.28 and a beta of 0.81. The company has a quick ratio of 1.06, a current ratio of 1.33 and a debt-to-equity ratio of 0.62. 
Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Friday, February 2nd. The company reported $0.98 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.94 by $0.04. Merck & Co., Inc. had a net margin of 6.40% and a return on equity of 28.61%. The firm had revenue of $10.43 billion for the quarter, compared to analyst estimates of $10.48 billion. During the same quarter last year, the business earned $0.89 earnings per share. Merck & Co., Inc.'s revenue was up 3.1% compared to the same quarter last year. sell-side analysts expect that Merck & Co., Inc. will post 4.16 EPS for the current year. 
The company also recently announced a quarterly dividend, which will be paid on Friday, April 6th. Investors of record on Thursday, March 15th will be given a dividend of $0.48 per share. The ex-dividend date is Wednesday, March 14th. This represents a $1.92 dividend on an annualized basis and a yield of 3.48%. Merck & Co., Inc.'s dividend payout ratio (DPR) is currently 105.49%. 
Merck & Co., Inc. declared that its board has authorized a share buyback program on Tuesday, November 28th that authorizes the company to buyback $10.00 billion in outstanding shares. This buyback authorization authorizes the company to buy shares of its stock through open market purchases. Shares buyback programs are typically an indication that the company's leadership believes its stock is undervalued. 
A number of equities research analysts have recently commented on the stock. ValuEngine cut shares of Merck & Co., Inc. from a "buy" rating to a "hold" rating in a report on Friday, February 2nd. Bank of America began coverage on shares of Merck & Co., Inc. in a report on Tuesday, November 28th. They set a "buy" rating and a $64.00 price target for the company. Morgan Stanley increased their price target on shares of Merck & Co., Inc. from $60.00 to $63.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 7th. DZ Bank raised shares of Merck & Co., Inc. from a "hold" rating to a "buy" rating in a report on Tuesday, February 13th. Finally, Sanford C. Bernstein reissued a "buy" rating and set a $64.00 price target on shares of Merck & Co., Inc. in a report on Wednesday, November 15th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and twelve have assigned a buy rating to the company's stock. Merck & Co., Inc. has a consensus rating of "Hold" and an average price target of $66.41. 
In related news, EVP Michael J. Holston sold 12,500 shares of the firm's stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $61.63, for a total transaction of $770,375.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website . Also, Director Wendell P. Weeks sold 5,000 shares of the stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $53.57, for a total transaction of $267,850.00. Following the transaction, the director now directly owns 5,100 shares in the company, valued at approximately $273,207. The disclosure for this sale can be found here . In the last 90 days, insiders have sold 82,500 shares of company stock worth $5,026,025. 0.25% of the stock is owned by company insiders. COPYRIGHT VIOLATION NOTICE: "Merck & Co., Inc. (NYSE:MRK) Position Trimmed by Legacy Private Trust Co." was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/03/16/merck-co-inc-mrk-position-decreased-by-legacy-private-trust-co.html. 
Merck & Co., Inc. Company Profile 
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Receive News & Ratings for Merck & Co. Inc.   analysts' ratings for Merck & Co. Inc. and related companies   daily email newsletter . Â«
